Prezzo AbbVie xStock
ABBVXRank 3456
AbbVie xStock (ABBVX) Grafico dei prezzi in tempo reale
AbbVie xStock (ABBVX) prezzo oggi è $210.43, con un volume di scambi in 24 ore di $11.17 e come tale AbbVie xStock (ABBVX) ha una capitalizzazione di mercato di $336.56K, dandogli una dominance di mercato di 0.0024%. Il prezzo di AbbVie xStock (ABBVX) ha registrato un -0.57% nelle ultime 24 ore.
ABBVX Dati sui prezzi
- 24h Turnover$11.17
- Massimo storico(ATH)$266.49
- Massimo 24h$211.65
- Il minimo storico(ATL)$156
- Minimo 24h$210.43
ABBVX Informazioni sulla capitalizzazione di mercato
- Cap. di mercato$336.56K
- Valutazione completamente diluita$68.07M
- Cap. di mercato/FDV0.49%
- Sentimento del mercatoNeutrale
ABBVX Offerta
- Fornitura in circolazione1.59K ABBVX
- Fornitura totale323.51K ABBVX
- Fornitura massima∞
*I dati sono solo di riferimento
Si prevede che AbbVie xStock (ABBVX) avrà una media di $210.43 in 2026, con una potenziale oscillazione tra il prezzo più basso $115.73 e il prezzo più alto $305.12. Entro 2031, il prezzo di AbbVie xStock(ABBVX) potrebbe raggiungere il $608.81, offrendo un potenziale rendimento +153.00% rispetto al prezzo AbbVie xStock odierno.
Anno | Prezzo minimo | Prezzo più alto | Average price | Modifica |
|---|---|---|---|---|
2026 | $115.73 | $305.12 | $210.43 | -- |
2027 | $157.24 | $373.77 | $257.77 | +22.00% |
2028 | $186.3 | $457.87 | $315.77 | +50.00% |
2029 | $232.09 | $526.08 | $386.82 | +83.00% |
2030 | $419.93 | $611.64 | $456.45 | +116.00% |
2031 | $464.62 | $608.81 | $534.05 | +153.00% |
AbbVie xStock(ABBVX) il prezzo è aumentato di -0.57% nelle ultime 24 ore e di +4.25% negli ultimi 7 giorni. Il prezzo di AbbVie xStock(ABBVX) è +1.30% negli ultimi 30 giorni, e -5.10% nell'ultimo anno.
Periodo di tempo | Importo residuo | Variazione % |
|---|---|---|
1H | +$0.01914 | +0.0091% |
24H | -$1.2 | -0.57% |
7D | +$8.57 | +4.25% |
30D | +$2.7 | +1.30% |
1Y | -$11.3 | -5.10% |
A proposito di AbbVie xStock (ABBVX)
Contratto
xswbinnky...eeqssqoie
Explorer
explorer.solana.com
Sito Web
xstocks.com
Notizie
Tag
AbbVie xStock (ABBVx) is a tracker certificate issued as Solana SPL and ERC-20 tokens. ABBVx tracks the price of AbbVie company stock (the underlying). ABBVx is designed to give eligible cryptocurrency market participants regulatory-compliant access to the price of AbbVie company stock, whilst maintaining the benefits of blockchain technology.
- GateNewsAccording to The Block, venture capital firm Andreessen Horowitz submitted an 18-page comment letter to the Commodity Futures Trading Commission on Friday, supporting federal oversight of prediction markets and opposing state-level crackdowns. A16z argued that cease-and-desist letters and proposed b
- GateNewsAccording to WisdomTree, the firm's crypto exchange-traded products (ETPs) registered net inflows of $137 million in the first quarter of 2026, a significant reversal from net outflows of $89 million in the same period last year. Total crypto ETP assets under management rose to approximately $1.8
- GateNewsAccording to its annual filing, European crypto asset manager CoinShares recorded gross assets under management of $7.4 billion in 2025, its first full-year report since completing a $1.2 billion merger with special purpose acquisition company Vine Hill and listing on Nasdaq under ticker CSHR
- GateNewsAccording to ChainCatcher, Elon Musk stated in an OpenAI lawsuit hearing that while some cryptocurrencies have value, the majority are scams. The remarks were made during cross-examination in Oakland, California court, amid discussions about OpenAI's early consideration of ICO-based
- GateNewsAccording to HyperInsight monitoring, on May 2, trader Huang Lixing (known as "Maji") increased his leveraged ETH long position to over $30 million with 25x leverage, entry price at $2,311 and liquidation price at $2,229. He also holds a 40x leveraged Bitcoin long position of $28.5 million with
- GateNewsAccording to BlockBeats, Berkshire Hathaway CEO Abel said on May 2 at the company's shareholder meeting that patience and capital discipline are among the firm's greatest advantages. He emphasized that opportunities will emerge over time, and the company will not rush to deploy capital into